1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

How do I...

Do you have questions on how to use the message boards? Want to know how to post, how to insert links, post polls, change your user options, etc.? Simply post your question here and we will answer as soon as possible.

Sort By:
Title ↓
Replies Views
Last Message
  1. WayneChesterbrook
    Replies:
    3
    Views:
    6,528
  2. Huskerlover
    Replies:
    0
    Views:
    1,400
  3. Anonymous
    Replies:
    0
    Views:
    1,324
  4. Anonymous
    Replies:
    9
    Views:
    14,170
  5. Anonymous
    Replies:
    0
    Views:
    1,993
  6. anonymous
    Replies:
    0
    Views:
    80
  7. Anonymous
    Replies:
    0
    Views:
    1,537
  8. Anonymous
    Replies:
    0
    Views:
    2,011
  9. anonymous
    Replies:
    0
    Views:
    348
  10. EmployeeforLife
    Replies:
    0
    Views:
    1,069
  11. DALLAS7
    Replies:
    0
    Views:
    1,079
  12. Keister
    Replies:
    0
    Views:
    811
  13. BlueDevil11
    Replies:
    0
    Views:
    569
  14. JoshSackman
    Replies:
    1
    Views:
    636
  15. Anonymous
    Replies:
    1
    Views:
    1,709
  16. QA2REP
    Replies:
    0
    Views:
    1,751
  17. scientist
    Replies:
    1
    Views:
    2,909
  18. Anonymous
    Replies:
    2
    Views:
    2,052
  19. Terry2
    Replies:
    3
    Views:
    1,340
  20. anonymous
    Replies:
    1
    Views:
    562

Thread Display Options

Loading...